Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026)
Quarterly results put Capital Expenditures at $32486.0 for Q1 2026, down 52.02% from a year ago — trailing twelve months through Mar 2026 was $697698.0 (down 26.05% YoY), and the annual figure for FY2025 was $732925.0, down 37.77%.
Immix Biopharma has reported Capital Expenditures over the past 5 years, most recently at $32486.0 for Q1 2026.
- Capital Expenditures reached $32486.0 in Q1 2026 per IMMX's latest filing, down from $165126.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $507151.0 in Q4 2024 and bottomed at $13177.0 in Q4 2023.
- Median Capital Expenditures over the past 4 years was $146378.0 (2025), compared with a mean of $195626.8.
- The largest annual shift saw Capital Expenditures skyrocketed 3748.76% in 2024 before it tumbled 77.57% in 2025.
- Over 4 years, Capital Expenditures stood at $13177.0 in 2023, then surged by 3748.76% to $507151.0 in 2024, then plummeted by 67.44% to $165126.0 in 2025, then tumbled by 80.33% to $32486.0 in 2026.
- Business Quant data shows Capital Expenditures for IMMX at $32486.0 in Q1 2026, $165126.0 in Q4 2025, and $372456.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 230.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | 32,486.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,486.00 |
| Mar 31, 2026 | 32,486.00 |
| Dec 31, 2025 | 165,126.00 |
| Dec 31, 2025 | 165,126.00 |
| Sep 30, 2025 | 372,456.00 |
| Sep 30, 2025 | 372,456.00 |
| Jun 30, 2025 | 127,630.00 |
| Jun 30, 2025 | 127,630.00 |
| Mar 31, 2025 | 67,713.00 |
| Mar 31, 2025 | 67,713.00 |
| Dec 31, 2024 | 507,151.00 |
| Dec 31, 2024 | 507,151.00 |
| Sep 30, 2024 | 271,542.00 |
| Sep 30, 2024 | 271,542.00 |
| Jun 30, 2024 | 97,074.00 |
| Jun 30, 2024 | 97,074.00 |
| Mar 31, 2024 | 301,913.00 |
| Mar 31, 2024 | 301,913.00 |
| Dec 31, 2023 | 13,177.00 |
| Dec 31, 2023 | 13,177.00 |
| Mar 31, 2021 | 802.00 |
| Mar 31, 2021 | 802.00 |